Published in J Immunol on June 01, 2008
Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators Inflamm (2010) 1.01
Accelerated wound healing mediated by activation of Toll-like receptor 9. Wound Repair Regen (2010) 0.97
Class I/II hybrid inhibitory oligodeoxynucleotide exerts Th1 and Th2 double immunosuppression. FEBS Open Bio (2012) 0.96
Overexpression of apolipoprotein A1 in the lung abrogates fibrosis in experimental silicosis. PLoS One (2013) 0.89
Effect of suppressive oligodeoxynucleotides on the development of inflammation-induced papillomas. Cancer Prev Res (Phila) (2011) 0.86
Transcriptomics analysis of lungs and peripheral blood of crystalline silica-exposed rats. Inhal Toxicol (2012) 0.84
Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus. Clin Exp Immunol (2010) 0.84
Synthetic oligodeoxynucleotides containing suppressive TTAGGG motifs inhibit AIM2 inflammasome activation. J Immunol (2013) 0.82
Inhibition of a C-rich oligodeoxynucleotide on activation of immune cells in vitro and enhancement of antibody response in mice. Immunology (2010) 0.81
Suppressive oligodeoxynucleotides promote the development of Th17 cells. PLoS One (2013) 0.80
Mammalian telomeric DNA suppresses endotoxin-induced uveitis. J Biol Chem (2010) 0.78
Suppressive oligodeoxynucleotides reduce lung cancer susceptibility in mice with silicosis. Carcinogenesis (2014) 0.77
Cell-Based Therapy for Silicosis. Stem Cells Int (2016) 0.77
Suppressive oligodeoxynucleotides synergistically enhance antiproliferative effects of anticancer drugs in A549 human lung cancer cells. Int J Oncol (2012) 0.75
Use of nanoparticles to deliver immunomodulatory oligonucleotides. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.75
Suppressive oligonucleotides inhibit inflammation in a murine model of mechanical ventilator induced lung injury. J Thorac Dis (2016) 0.75
Silica particles cause NADPH oxidase-independent ROS generation and transient phagolysosomal leakage. Mol Biol Cell (2015) 0.75
The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol (2007) 16.46
Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol Biomarkers Prev (2002) 3.12
Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med (2010) 2.61
Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst (2008) 2.25
CpG DNA as a vaccine adjuvant. Expert Rev Vaccines (2011) 2.17
TLR-based immune adjuvants. Vaccine (2010) 2.10
Retracted Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res (2009) 2.00
Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol (2003) 1.84
Reduced inflammation and lymphoid tissue immunopathology in rhesus macaques receiving anti-tumor necrosis factor treatment during primary simian immunodeficiency virus infection. J Infect Dis (2012) 1.80
Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat Med (2012) 1.74
Gadd45a protects against UV irradiation-induced skin tumors, and promotes apoptosis and stress signaling via MAPK and p53. Cancer Res (2002) 1.71
Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J Virol (2010) 1.65
Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol (2012) 1.62
IRF-5 and NF-κB p50 co-regulate IFN-β and IL-6 expression in TLR9-stimulated human plasmacytoid dendritic cells. Eur J Immunol (2013) 1.62
Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal Physiol (2008) 1.59
Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest (2010) 1.58
DNA containing CpG motifs induces angiogenesis. Proc Natl Acad Sci U S A (2002) 1.55
Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc Natl Acad Sci U S A (2008) 1.51
CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol (2002) 1.48
Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol (2002) 1.48
Human immunodeficiency virus type 1 nucleocapsid zinc-finger mutations cause defects in reverse transcription and integration. Virology (2006) 1.48
Toll-like receptor 9 signaling activates NF-kappaB through IFN regulatory factor-8/IFN consensus sequence binding protein in dendritic cells. J Immunol (2004) 1.45
Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol (2004) 1.44
Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res Hum Retroviruses (2004) 1.42
Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. Arthritis Rheum (2005) 1.40
Immunobiotic Lactobacillus jensenii elicits anti-inflammatory activity in porcine intestinal epithelial cells by modulating negative regulators of the Toll-like receptor signaling pathway. Infect Immun (2011) 1.38
Are all hypotheses generated before data analysis prospective? J Clin Oncol (2002) 1.38
Transcriptional regulation of the human TLR9 gene. J Immunol (2004) 1.38
TRAF4 acts as a silencer in TLR-mediated signaling through the association with TRAF6 and TRIF. Eur J Immunol (2005) 1.36
Preconceptional fasting of fathers alters serum glucose in offspring of mice. Nutrition (2006) 1.35
Inhibition of human neutrophil IL-8 production by hydrogen peroxide and dysregulation in chronic granulomatous disease. J Immunol (2005) 1.34
Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation. J Exp Med (2002) 1.30
CXCL16 influences the nature and specificity of CpG-induced immune activation. J Immunol (2006) 1.30
Comparative analysis of HIV-1 viral load assays on subtype quantification: Bayer Versant HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 Monitor version 1.5. J Acquir Immune Defic Syndr (2002) 1.30
The adjuvant activity of CpG DNA requires T-bet expression in dendritic cells. Proc Natl Acad Sci U S A (2005) 1.30
Mutation of amino acids in the connection domain of human immunodeficiency virus type 1 reverse transcriptase that contact the template-primer affects RNase H activity. J Virol (2003) 1.28
Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock. J Immunol (2005) 1.27
CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J Immunol (2003) 1.22
Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine (2007) 1.21
Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Hum Gene Ther (2003) 1.17
Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol (2003) 1.17
Effect of suppressive DNA on CpG-induced immune activation. J Immunol (2002) 1.16
CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect Immun (2005) 1.16
Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-gamma- and IL-12-mediated signaling. J Immunol (2004) 1.15
Mutations in the 5' end of the human immunodeficiency virus type 1 polypurine tract affect RNase H cleavage specificity and virus titer. J Virol (2003) 1.13
Mutations at position 184 of human immunodeficiency virus type-1 reverse transcriptase affect virus titer and viral DNA synthesis. Virology (2004) 1.13
Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo. J Leukoc Biol (2009) 1.12
CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection. J Immunol (2005) 1.08
Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides. Arthritis Rheum (2002) 1.08
gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin Cancer Res (2004) 1.08
CpG-mediated changes in gene expression in murine spleen cells identified by microarray analysis. Mol Immunol (2006) 1.07
Effects of mutations in the G tract of the human immunodeficiency virus type 1 polypurine tract on virus replication and RNase H cleavage. J Virol (2004) 1.06
Suppressive oligonucleotides protect against collagen-induced arthritis in mice. Arthritis Rheum (2004) 1.06
CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. Eur J Immunol (2002) 1.04
CpG RNA: identification of novel single-stranded RNA that stimulates human CD14+CD11c+ monocytes. J Immunol (2005) 1.03
Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med (2006) 1.02
Effect of CpG oligonucleotides on vaccine-induced B cell memory. J Immunol (2008) 1.00
TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells. J Immunol (2003) 1.00
Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. Arthritis Rheum (2003) 1.00
Toll-like receptor-2-activating bifidobacteria strains differentially regulate inflammatory cytokines in the porcine intestinal epithelial cell culture system: finding new anti-inflammatory immunobiotics. FEMS Immunol Med Microbiol (2011) 1.00
Toll-like receptor 2 and 9 are expressed and functional in gut-associated lymphoid tissues of presuckling newborn swine. Vet Res (2006) 0.99
Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin Immunol (2003) 0.99
Combining mutations in HIV-1 reverse transcriptase with mutations in the HIV-1 polypurine tract affects RNase H cleavages involved in PPT utilization. Virology (2006) 0.98
A novel role for IL-22R1 as a driver of inflammation. Blood (2010) 0.98
Pertussis toxin is superior to TLR ligands in enhancing pathogenic autoimmunity, targeted at a neo-self antigen, by triggering robust expansion of Th1 cells and their cytokine production. J Immunol (2006) 0.98
Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. J Virol (2006) 0.97
Accelerated wound healing mediated by activation of Toll-like receptor 9. Wound Repair Regen (2010) 0.97
Modeling clinically heterogeneous presenilin mutations with transgenic Drosophila. Curr Biol (2006) 0.97
Class I/II hybrid inhibitory oligodeoxynucleotide exerts Th1 and Th2 double immunosuppression. FEBS Open Bio (2012) 0.96
Toll-like receptor 2 is expressed on the intestinal M cells in swine. Biochem Biophys Res Commun (2005) 0.96
Blocking of the TLR5 activation domain hampers protective potential of flagellin DNA vaccine. J Immunol (2007) 0.96
Strong immunostimulation in murine immune cells by Lactobacillus rhamnosus GG DNA containing novel oligodeoxynucleotide pattern. Cell Microbiol (2005) 0.95
Immunobiotic lactic acid bacteria beneficially regulate immune response triggered by poly(I:C) in porcine intestinal epithelial cells. Vet Res (2011) 0.95
Short- and long-term changes in gene expression mediated by the activation of TLR9. Mol Immunol (2009) 0.95
β-Defensin 2 and 3 promote the uptake of self or CpG DNA, enhance IFN-α production by human plasmacytoid dendritic cells, and promote inflammation. J Immunol (2013) 0.94
CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity. Cancer Immunol Immunother (2011) 0.94
Differential involvement of Th1 and Th17 in pathogenic autoimmune processes triggered by different TLR ligands. J Immunol (2013) 0.93
Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J Virol (2003) 0.93
C/EBPγ suppresses senescence and inflammatory gene expression by heterodimerizing with C/EBPβ. Mol Cell Biol (2013) 0.93
Potential of transfected muscle cells to contribute to DNA vaccine immunogenicity. J Immunol (2007) 0.92
Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen. Infect Immun (2004) 0.92
Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. J Immunol (2002) 0.92
3'UTR elements inhibit Ras-induced C/EBPβ post-translational activation and senescence in tumour cells. EMBO J (2011) 0.91
In vivo role of p38 mitogen-activated protein kinase in mediating the anti-inflammatory effects of CpG oligodeoxynucleotide in murine asthma. J Immunol (2002) 0.91
Ontogeny-driven rDNA rearrangement, methylation, and transcription, and paternal influence. PLoS One (2011) 0.91
Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev Vaccines (2013) 0.90
Global changes in gene expression and synergistic interactions induced by TLR9 and TLR3. Mol Immunol (2009) 0.90
Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients. PLoS One (2009) 0.90
Suppressive oligodeoxynucleotides inhibit CpG-induced inflammation of the mouse lung. Crit Care Med (2004) 0.89
Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells. J Immunother (2003) 0.89
Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides. Curr Opin Mol Ther (2004) 0.89
Alternate polypurine tracts affect rous sarcoma virus integration in vivo. J Virol (2006) 0.89
CpG oligodeoxynucleotides improve the survival of pregnant and fetal mice following Listeria monocytogenes infection. Infect Immun (2004) 0.88
Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques. Vaccine (2006) 0.88
CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques. AIDS (2004) 0.88